← Patent-cliff monitor small molecule LYNPARZA OLAPARIB
Loss of exclusivity October 2041 latest FDA-listed patent expiry
Company ASTRAZENECA PHARMACEUTICALS LP
Drug detail Brand name LYNPARZA Active ingredient OLAPARIB Strength 100MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval August 2017 Marketing status RX
Listed patents Patent Expires Type 11970530 October 2041 use U-3931 8859562 August 2031 use U-3333 8475842 December 2029 product 11975001 October 2029 product 11633396 October 2029 product 12048695 October 2029 product 12178816 October 2029 product 12144810 October 2029 product 7449464 September 2027 substance, product 8071579 August 2027 use U-3333 8143241 August 2027 use U-3333
Regulatory exclusivity Code Expires ODE-306 May 2027 ODE-283 December 2026 I-914 May 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.